Pharmaceutical Technology

JANUARY 10, 2023

Many of the current existing therapies are often viewed by physicians as not optimal to addressing the needs of patients, and challenges remain such as improving patient compliance, safety profile, and addressing comorbidities of T2D. billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%.

Marketing 52

Marketing Physicians Leads Sales 52

European Pharmaceutical Review

AUGUST 30, 2022

It was about solving cold-chain logistical challenges and ensuring the vaccine doses themselves could be administered easily and efficiently with minimal discomfort for patients. million by 2029, up from $122.287 million in 2021. We have been given a crash course in how to deliver vaccine doses successfully to billions of people.

Management 119

Management Manufacturing Marketing Side effects 119

Pharmaceutical Technology

FEBRUARY 3, 2023

However, after almost seven years of staving off competitors through patents and litigation, Humira’s market-leading position in the US will be affected as Amgen’s adalimumab biosimilar, Amjevita, started to roll out on January 31, 2023. billion in 2022.

Marketing 52

Marketing Sales Patients Physicians 52

pharmaphorum

DECEMBER 20, 2022

Wedbush Securities recently forecast more than $1 billion in 2029 sales for ensifentrine in the US alone, assuming a launch in the first quarter of 2024, and said today the stock could easily reach $30. COPD is the third leading cause of death worldwide, with 3.23 and drive the company’s market cap to almost $1.5

Pharma 59

Pharma Sales Leads Marketing 59

PM360

APRIL 7, 2023

However, Medicare will only be able to negotiate prices for 10 Part D drugs in 2026, another 15 Part D drugs in 2027, another 15 Part D and Part B drugs in 2028, and another 20 Part D and Part B drugs for 2029 and subsequent years. Impact Beyond Medicare The IRA won’t just impact negotiation with the government either. Reference: 1.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

Medico Reach

OCTOBER 17, 2022

However, this can lead to several issues, such as: Implantation resistance due to reactionary metabolism Allergic reactions to the nickel component found in stainless steel composites Widespread bone destruction due to immunological responses to cobalt particles. billion by 2029. The US-based Enovis is leading this new development.

Medical 52

Medical Food and Drug Administration Healthcare Healthcare 52

European Pharmaceutical Review

NOVEMBER 16, 2023

billion by 2029. This requires modulating different components of the human immune system in a way that can address different patient segments, as the immune system is dysregulated in different ways across different tumour types. According to Data Bridge Market Research, the haematology /oncology market will value $14.83

Medicine 52

Medicine Medical Manufacturing Patients 52

Pharmaceutical Technology

APRIL 4, 2023

of NSCLC patients with exon 19 and 21 mutations develop resistance mutations at C797S. While Scorpion will lead the development of STX-721, Pierre Fabre will handle STX-241. billion in 2029. Up to 12.5% Scorpion received a $65 million upfront payment, with the potential to earn up to $553 million in milestones.

Food and Drug Administration 52

Food and Drug Administration Biopharma FDA Pharmaceutical 52

Pharmaceutical Technology

MAY 17, 2023

Orphan drug designations are granted to drugs that target rare disorders with fewer than 200,000 patients in the US. Primary biliary cholangitis is a rare autoimmune disease where small bile ducts are injured by the patient’s own immune system. This results in bile buildup in the liver and can lead to scarring. billion in 2029.

Food and Drug Administration 52

Food and Drug Administration FDA Pharmaceutical Prospecting 52

Clarivate

OCTOBER 17, 2024

Pre-waiver, for behavioral health visits, patients were required to have received an in-person evaluation six months before initiating telehealth, followed by an in-person visit annually. Waivers enable access to medications for hundreds of thousands of patients nationwide for a variety of medical diagnoses including substance use disorder.

Healthcare 52

Healthcare Healthcare Government Insurance 52